ANTHOGYR

Manufacturer adverse-event records for ANTHOGYR come from the U.S. Food & Drug Administration (FDA) MAUDE database via openFDA, refreshed March 2026 - see our methodology. Not medical advice.

FDA MAUDE device safety record · 2016–2026 · heavy-book · quiet Death-code · injury-heavy

Death-code intensity

ANTHOGYR is quieter on Death-coded events

Death-coded event_type rows are 0 of 55,596 (0.00% · quiet tercile among 443 manufacturers). Absolute volume is heavy-book.

What the Death-code reading shows for ANTHOGYR

The standout signal for ANTHOGYR is Death-code intensity: 0.00% of 55,596 reports (quiet tercile), while absolute volume is heavy-book.

As a heavy-book manufacturer, portfolio size and reporting obligations inflate absolute counts - pair ANTHOGYR with device-family pages before treating company totals as a safety verdict. Event_type Death and Injury are one code per report; Patient Outcomes below use a separate FDA population.

Reports span 2 device types, led in this extract by Injury at 53,207 (95.7% of event_type total). Peak single-year volume reaches 13,431 reports across 11 years. These are raw FDA submissions, not adjudicated findings. Snapshot . Verify current communications on the FDA MDR page.

55,596
Total Reports
0
Event-type Death
53,207
Injury Reports
2
Device Types

Event Types

Injury 53,207 (95.7%)
Malfunction 2,389 (4.3%)

Patient Outcomes

FDA patient-outcome codes (separate from event_type). Percentages use this chart's row total.

Required Intervention 46,771 (84.2%)
8,689 (15.6%)
Other 65 (0.1%)
R 29 (0.1%)
Congenital Anomaly 8 (0.0%)
Disability 1 (0.0%)
Hospitalization 1 (0.0%)

Yearly Trend

16
2016: 57
17
2017: 1,279
18
2018: 1,526
19
2019: 2,907
20
2020: 2,425
21
2021: 5,265
22
2022: 7,792
23
2023: 8,980
24
2024: 9,720
25
2025: 13,431
26
2026: 2,214